W
Wendy Lea Corbett
Researcher at Hoffmann-La Roche
Publications - 24
Citations - 1184
Wendy Lea Corbett is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Glucokinase & Phenyl group. The author has an hindex of 15, co-authored 24 publications receiving 1137 citations. Previous affiliations of Wendy Lea Corbett include University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
Allosteric Activators of Glucokinase: Potential Role in Diabetes Therapy
Joseph Grimsby,Ramakanth Sarabu,Wendy Lea Corbett,Nancy-Ellen Haynes,Fred Thomas Bizzarro,John W. Coffey,Kevin Richard Guertin,Darryl W. Hilliard,Robert Francis Kester,Paige Erin Mahaney,Linda Marcus,Lida Qi,Cheryl Spence,John Tengi,Mark A. Magnuson,Chang An Chu,Mark T. Dvorozniak,Franz M. Matschinsky,Joseph F. Grippo +18 more
TL;DR: In several rodent models of type 2 diabetes mellitus, GKAs lowered blood glucose levels, improved the results of glucose tolerance tests, and increased hepatic glucose uptake, which may lead to the development of new drug therapies for diabetes.
Journal ArticleDOI
Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
Ramakanth Sarabu,Fred Thomas Bizzarro,Wendy Lea Corbett,Mark T. Dvorozniak,Wanping Geng,Joseph F. Grippo,Nancy-Ellen Haynes,Stanley D. Hutchings,Lisa M. Garofalo,Kevin Richard Guertin,Darryl W. Hilliard,Marek M. Kabat,Robert Francis Kester,Wang Ka,Zhenmin Liang,Paige Erin Mahaney,Linda Marcus,Franz M. Matschinsky,David J Moore,Jagdish Kumar Racha,Roumen Nikolaev Radinov,Yi Ren,Lida Qi,Michael Pignatello,Cheryl Spence,Thomas G. Steele,John Tengi,Joseph Grimsby +27 more
TL;DR: Piragliatin was found to lower pre- and postprandial glucose levels, improve the insulin secretory profile, increase β-cell sensitivity to glucose, and decrease hepatic glucose output in patients with T2D.
Patent
Fused heteroaromatic glucokinase activators
Wendy Lea Corbett,Joseph Grimsby,Nancy-Ellen Haynes,Robert Francis Kester,Paige Erin Mahaney,Ramakanth Sarabu +5 more
TL;DR: Glucokinase activating amides are useful for increasing insulin secretion in the treatment of type II diabetes as mentioned in this paper. But they are not suitable for patients with high blood cholesterol levels, such as Type II diabetes.
Patent
Substituted phenylacetamides and their use as glucokinase activators
Wendy Lea Corbett,Joseph Grimsby,Nancy-Ellen Haynes,Robert Francis Kester,Paige E. Mahaney,Jagdish Kumar Racha,Ramakanth Sarabu,Ka Wang +7 more
TL;DR: In this paper, the glucokinase activators of the formula (I) were evaluated for the treatment of type II diabetes, wherein formula (II) represents a substituted group, an oxa-cycloalkyl group or a thia-cycloencyl group.
Patent
5-substituted-pyrazine or pyridine glucokinase activators
Shaoqing Chen,Wendy Lea Corbett,Kevin Richard Guertin,Nancy-Ellen Haynes,Robert Francis Kester,Francis A. Mennona,Steven Gregory Mischke,Yimin Qian,Ramakanth Sarabu,Nathan Robert Scott,Kshitij Chhabilbhai Thakkar +10 more
TL;DR: In this article, a compound according to formula (I) where the substituent designations are provided in the specification is provided, said compounds being glucokinase activators which are useful in the treatment of type II diabetes.